Videos

Attorney Kenton H. Steele, Esq, discusses his recent Urology Times® column.

Rena Malik, MD, discusses findings from a recent Urology Practice study.

Researchers evaluated the use of interprofessional consultations within the specialty of urology.

Adam J. Gadzinski, MD, MS, highlights positive outcomes of telemedicine multidisciplinary urologic cancer clinics implemented by the University of Washington/Seattle Cancer Care Alliance.

Only 5% of websites studied discuss risks of treatments, investigators found.

Ramaprasad Srinivasan, MD, PhD, provides background on the prognosis and treatment of patients with Von Hippel-Lindau–associated renal cell carcinoma and highlights the novel agent MK-6482.

Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.

Vikram M. Narayan, MD, discusses how smoking is the most significant known risk factor for bladder cancer.

Reza Z. Goharderakhshan, MD, discusses how patient compliance for recommended studies increased from less than 10% to 82% following implementation of the program.

“Listen. Be emphatic. Be transparent,” Pansy Uberoi, MD, MPH, advises in this interview.

Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.

Over 90% of patients in a phase 2 trial had at least some decrease in the size of target lesions.

Victoria S. Edmonds and Tobias Köhler, MD, MPH, discuss trends in reimbursement for men's health procedures from 2002 to 2020.

The comprehensive review includes key developments in both clear cell and non-clear cell histology.

Gomella looks back on the year's top headlines in bladder cancer, from FDA approvals to notable clinical trial results.